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Purpose: A combination of extracts, from two plant species, ie, Coffea arabica and Larrea 
divaricata (Jarilla) (ECOHAIR®), is being successfully used in Argentina as a cosmetic for hair 
recovery in androgenic and areata alopecia, and for eyelash and eyebrow growth. The objectives 
of this prospective study were to evaluate the capacity of Jarilla–Coffea extract gel of improving 
hair growth in relation to thickness, appearance of new hair, and hair length in comparison with 
a placebo in premenopausal and postmenopausal volunteers and to identify possible signs of 
ocular adverse local reactions related to the application of the gel.
Volunteers and methods: An open-label, placebo-controlled, prospective study was per-
formed in healthy premenopausal and postmenopausal women during a daily administration 
period of 2 months (eyebrow growth) and 3 months (eyelash growth). The thickness of hair was 
determined using a video microscope MedicalScope®. The appearance of new hairs and total 
area with hair in eyebrow and eyelash length were quantified using a photographic record with 
Fotofinder® (Germany). The number of volunteers presenting variation in growth of new hair 
and length were also recorded.
Results: The product significantly increased the thickness of eyebrows (20% in 80% women) and 
eyelashes (19.44% in 100% of women). The gel also increased the appearance of new hairs, total 
area with hair, and length but there was no statistical difference between treatment and placebo.
Conclusion: The gel was capable of improving growth of eyelashes and eyebrows by induc-
ing principally hair thickening without causing local adverse effects in a high percentage of 
volunteers.
Keywords: eyelash thickness, eyebrow thickness, plant extracts, menopause, adverse effects, 
cosmetic
Introduction
Both men and women suffer from hypotrichosis, which comprises either hair loss 
and/or thinning. This phenomenon, which affects not only the scalp but also eyelashes 
and eyebrows, is a result of an imbalance between cell proliferation and death. It is 
known that hair is involved in skin protection and thermal regulation. Especially, 
the eyelashes protect the eyes from light and dust, while the eyebrows protect the 
eyes from the sweat dripping down from the forehead. When hypotrichosis occurs, a 
deleterious effect on the patient’s esthetic appearance also ensues. Hypotrichosis in 
eyelashes and eyebrows may be caused by ophthalmological infections and inflam-
matory process but also by dermatological diseases such as atopic dermatitis, contact 
dermatitis, psoriasis, lichen planus, and seborrheic dermatitis. Also hypotrichosis 
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may be attributed to telogen effluvium caused by intake of 
drugs such as anticoagulants, lipid-lowering agents, anti-
hypertensive agents (propranolol), valproate, barbiturates, 
bromocriptine, immunosuppressants, botulinum toxin, 
NSAIDs, and hormone imbalance.1
It is known that premenopausal, perimenopausal, and 
postmenopausal women suffer from hypotrichosis as a con-
sequence of hormone misbalance; under this situation, some 
changes in skin such as increased dryness and roughness, 
decreased elasticity, warts, freckles, increased wrinkles, loss 
and graying of head hair, and lengthening of eyebrows and 
eyelashes are observed.2,3
Under these situations, extensions, masks of different types, 
eyelash bends, transplants, and permanent dyes are used on 
both eyelashes and eyebrows. One of the current products used 
to promote eyelash growth is a bimatoprost solution, which is 
a synthetic analog of prostaglandin F2α used for the treatment 
of glaucoma. As side effect, bimatoprost is known to induce 
hair growth. The Food and Drug Administration (FDA) has 
approved it to be used in a 0.03% solution to stimulate the 
growth, thickness, and pigmentation of eyelashes in patients 
with hypotrichosis. However, the compound stimulates hair 
growth in some patients while in those with alopecia areata it 
is ineffective. On the other hand, when the product makes con-
tact with the eye, serious adverse effects can occur. Analogs of 
prostaglandins (PGs) and prostanoids are associated with local 
and systemic effects not only when administered topically in the 
eye but also when placed in the eyelash insertion. These analogs 
can cause hyperpigmentation of the iris, as a consequence of 
an increase in melanogenesis, conjunctival hyperemia, eye 
dryness, erythema, itching, and uveitis. They have also been 
reported to cause headache, hirsutism, hepatic impairment, 
and to increase the sensitivity to herpes simplex virus (HSV) 
infection. In addition, it has been observed that both bimatoprost 
and latanoprost, other prostanoid, cause HSV dermatitis of the 
periocular skin.4 Taking these observations into account, the use 
of these prostanoids to promote the growth of the eyelashes is 
contraindicated in patients suffering from inflammatory diseases 
or from viral infections. Moreover, the commercially available 
products contain benzalkonium chloride as antibacterial, which 
has cytotoxic effect on the cornea and can cause erosion of the 
epithelium, irritation, and eye dryness.5
The prostanoids cannot be used during pregnancy because 
it has been classified by the FDA as a class C drug, since it 
is likely to cause malformations in the fetus.6
To date, no innocuous effective products to promote eye-
lash or eyebrow growth have been developed. A combination 
of extracts obtained from two plant species, ie, Coffea arabica 
and Larrea divaricata (Jarilla) (ECOHAIR®), is being suc-
cessfully used in Argentina, by Garre-Guevara Laboratory, 
as cosmetic, for hair recovery in scalp in cases of androgenic 
and areata alopecia and for eyelash and eyebrow growth. 
The effectiveness of the product in scalp alopecia has been 
verified not only in in vivo alopecia models in C3H mice but 
also in a clinical trial.7,8
To provide scientific support for its effect in eyelash and 
eyebrow growth, the product was tested in premenopausal 
and postmenopausal healthy women. The primary objective 
of this prospective study was to evaluate the capacity of 
Jarilla–Coffea extract gel for improving hair growth in rela-
tion to thickness, appearance of new hairs, and hair length 
in comparison with a placebo. The secondary objective was 
to identify possible signs of ocular adverse local reactions 
related to the application of the gel.
Volunteers and methods
study design
An open-label, placebo-controlled, prospective study was per-
formed to evaluate the efficacy of Jarilla–Coffea extract gel 
on eyelashes and eyebrows in premenopausal and postmeno-
pausal healthy women during a daily administration period 
of 2 months, in the case of eyebrow growth, and 3 months, 
in the case of eyelash growth. These evaluation periods are 
in accordance with the product prospectus.
ethical considerations and good clinical 
practices
This study was conducted in accordance with the intent and 
purpose of Good Clinical Practice regulations described in Title 
21 of the US Code of Federal Regulations, the requirements of 
the Declaration of Helsinki (1964), Amendments Tokyo (1975), 
Venice (1983), and Hong Kong (1989), Seúl (2008), and for 
CLAIM Standard Operating Procedures and National Laws: 
“Guía de Buenas Prácticas de Investigación Clínica en Seres 
Humanos”, in accordance to Resolution 1490/2007, published 
in “Boletín Oficial de la República Argentina” 14/11/2007, page 
6. The study was approved by a committee of independent eth-
ics, which assessed the study protocol and informed consent. 
Once the protocol was approved by the independent Ethics 
Committee or institutional review board (CLAIM’s Institutional 
Ethics Committee), the acceptance of the informed consent of 
the volunteer was obtained, in which, all the aspects making the 
study, all subjects and related research on which it requires infor-
mation, and what was done with a terminology was explained 
in a clearly understandable manner to the volunteer. Informed 
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a natural product that improves eyelash and eyebrow appearance
Products under study
The products used in this study were supplied by the Garre-
Guevara Laboratory. The products were identified as Jarilla–
Coffea extract eyebrows (PE928061A) and Jarilla–Coffea 
extract eyelashes (PE038061) fashioner gels and placebo. 
Both gels were viscous lotions slightly colored with penetrat-
ing odor. The placebo used was glycerin USP.
Volunteers
Volunteers were recruited during a period of 3 months (July 
2016 to September 2016). The study sample comprised ten 
women volunteers aged between 44 and 60 years (mean: 
51.2±1.54). One volunteer was withdrawn from the study due 
to a lack of adherence, so the sample size was then reduced 
to nine volunteers.
Before enrolling in the trial, all volunteers were informed 
about the study and signed an informed consent. All vol-
unteers were subjected to a thorough clinical revision. The 
following inclusion criteria were employed: 1) age: to be 
between 40 and 60 years; 2) volunteers with low density hair 
in eyelashes and eyebrows; 3) to have signed the informed 
consent form; and 4) volunteers who frequently used cosmet-
ics and agreed to comply with the clinical trial requirements. 
Exclusion criteria were: 1) presence of any medical condition, 
or the ingestion or application of any medication by either 
the oral or the ocular route, such as steroidal and NSAIDs; 2) 
diagnosis of psoriasis, eczema, atopic dermatitis, folliculitis, 
lentigines, eye dryness, or ocular allergic diseases; 3) suffer 
from diabetes, asthma, or respiratory allergic diseases; 4) to 
have received treatments with immunosuppressant drugs as a 
consequence of organ transplantation; and 5) have a clinical 
record of cutaneous reactions after cosmetics application.
study objectives and assessments
Volunteers were treated with Jarilla–Coffea extract eyebrow 
or eyelash gel on a daily basis, once a day, during 60 con-
secutive days with the eyebrow gel, or during 90 consecutive 
days with the eyelash gel. Two main variables were observed: 
1) efficacy in relation to hair growth defined as thickness, 
appearance of new hair, area with hairs and hair length; and 
2) safety and tolerability. The thickness of eyebrows and 
eyelashes was determined by a noninvasive methodology 
using a video microscope MedicalScope® with magnifica-
tion of 200×. A calibrated micrometer scale having a least 
measurement of 0.01 mm was incorporated in the software 
of the video microscope and the diameter of at least ten hairs, 
from a same zone of the eyebrow or the eyelash, was mea-
sured always at the same position close to their bases using 
the measuring eyepiece. An average of the measurements was 
obtained for each volunteer. Images were registered under 
CD protocol no. 0164-16-12E1 (eyebrow) and no. 0164-16-
01E2 (for eyelash) on day 0 (T
0
) and on day 60 (T
60
) or on 
day 90 (T
90
), respectively. The appearance of new hairs and 
total area with hair, and eyelash length were quantified using 
a photographic record with Fotofinder® (Fotofinder Systems 
GmbH, Bad Birnbach, Germany). The number of patients 
presenting variation in growth of new hair and length were 
also recorded.
Women were instructed to apply the product on the right 
eyebrows or eyelashes and to treat the left ones with the placebo, 
using the application instructions specified in the prospectus, 
that is: 1) daily application; 2) apply the product directly on the 
selective zone of eyebrows or eyelashes; 3) wash their hands 
between the application of placebo and treatment; 4) remove the 
excess of product; and 5) leave the product applied for 15–20 
minutes. During the study period, women were forbidden to 
use other products or make up and to have sunbath.
safety studies
Volunteers were subjected to ophthalmologic studies. First, a 
clinical history was obtained through examination of ocular 
surface with a slit lamp.
An evaluation of ocular surface was done after the treat-
ment with the product. Daily appointments were made with 
each volunteer during the first and third week after treatment. 
The presence of two clinical signs and two symptoms were 
considered positive for side effects.
Scales of signs and symptoms that were used to evaluate 
side effects are shown in Table 1:
Table 1
Scales of signs and symptoms 




1 Present without discomfort
2 Present with discomfort without 
interfering with daily activities
3 Present with discomfort and 




2 Visible but not severe




2 Visible but not severe
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To determine the presence of signs and symptoms, an 
instrumental analysis was done with a tearscope, which 
allowed evaluating the lachrymal film stability through the 
interference of colors produced by the instrument on the 
lachrymal film when the film is disrupted. A crystallization 
test was also done, which allows determining the quality of 
the lachrymal film. Four types of lachrymal crystallization 
are known:
Type I: like a tree with ramifications.
Type II: like type I but with less ramifications with a few 
small leaves.
Type III: partial crystallization without fern formation.
Type IV: no crystallization.
statistical analysis
A level of significance of 0.05 was employed in the hypoth-
esis test. Percent variations (PVs) were determined for each 
volunteer employing the following formula:
 Percent variation = [(effect T
F
 / effect T
0
) −1] × 100 
The mean PV was calculated as the mean of individual 
PV (μPV = [(Σ PV) / n], but not as PV of means PVμ = [(μ 
T
F
) / (μ T
0
) − 1] × 100, where T
0
: basal time, T
F
: time at 90 or 
60 days of application. The mathematical analysis was done 
with IBM SPSS Statistics 22 statistical package.
To determine if the increase in the mean thickness dur-
ing the treatment was greater than that obtained with the 
placebo, the linear generalized model for repeated measures 














, respectively. This percent change was 
about 19.44% (Table 2 and Figure 1A). All women displayed 
increased eyelash thickness.





; the PV was 0% (Table 2 and Figure 1A). 
No women treated with placebo presented any change in 
eyelashes thickness. The results obtained with the active 
principle and the placebo are shown in a representative 
micrograph (Figure 2C).
To determine whether the increase in the mean thickness 
during the treatment was greater than that obtained with the 
placebo LGMRM was applied. The differences between 
treatment and placebo were highly significant (P<0.001). 





 were significantly different (P<0.001, 
Student’s t-test).
eyelash maximal length
For the test product, the maximal eyelashes length means 




, respectively. The 
percent change was 3.59% (Table 3 and Figure 1B). About 
55.6% of volunteers presented an increase in the maximal 
eyelashes length.
For the placebo, the maximal eyelash length means were 




, respectively. The PV 
was –1.09% (Table 3 and Figure 1B). The effects obtained 
with the active principle and the placebo are shown in a 
representative micrograph taken with a Fotofinder® camera 
(Figure 2A, B).
To determine whether the increase in the mean maximal 
length obtained after treatment with the product was higher 
than that obtained with the placebo LGMRM was applied. 




The active principle induced an increase in the eyebrow 
thickness of 20% in 80% of volunteers (Table 4 and Figure 





, respectively. A PV mean of 9.16% was 
observed (Table 4).





. No PV was assigned in 100% of the volunteers (Table 4 
and Figure 3A, B, E, F).
To determine whether the increase in the mean thick-
ness after the treatment was higher than that obtained with 
the placebo LGMRM was applied. There was difference 
between mean values after treatment with the product and 
the placebo (P<0.001).
Table 2 eyelash thickness: statistical descriptors
N Minimum Maximum Mean SD
active T0 9 0.04 0.06 0.0500 0.00707
active TF 9 0.05 0.07 0.0594 0.00635
PV TF/T0 9 8.33% 25.00% 19.44% 4.93077%
Placebo T0 9 0.04 0.07 0.0506 0.00950
Placebo TF 9 0.04 0.07 0.0506 0.00950
PV TF/T0 9 0.00% 0.00% 0.00% 0.00000%
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a natural product that improves eyelash and eyebrow appearance
eyebrow new hairs
A 60% of women treated with the gel presented an increase 
in the number of hairs in the eyebrows; the mean new hair 




, respectively, with a 
mean increment value of 12.57% and a maximal increment 
of 56% (Table 5 and Figure 3A–D). Moreover, the mean 





, respectively, with a percent increase of 
3.94% and a maximal increment of 62%. In this case, 50% 
of volunteers presented a change.
To determine whether the increase in the mean value of 
new hairs after the treatment was higher than that obtained 
with the placebo LGMRM was applied. There was no differ-
ence between treatment and placebo (P=0.749).
Total area with hair in eyebrows
The mean total areas with hair obtained after treatment with 





The mean percent increase was 15.53%, with a maximum 
value of 132% (Table 6). This change was observed in 50% 
of volunteers (Figure 3C, D).
For the placebo, the total areas with hair means were 




, respectively. The mean percent 
increase was 5.69%, with a maximum value of 84%. This 
change was observed in 50% of volunteers (Figure 3C, D).
To determine whether the increase in the mean total area 
with hair after the treatment with the product was greater than 
that obtained with the placebo LGMRM was applied. There 
was no difference between the total area with hair between 
treatment and placebo (P=0.907).
safety studies
When applied on the eyelashes, the product did not cause any 
ocular adverse reactions. The lachrymal film in all volunteers 
did not present any alteration. The crystallization was type 
I in all cases. In addition, there was no difference – in the 
effects obtained on the eyelids and the orbital ledge skin – of 
product treated and placebo.
Discussion
In this work, the efficacy of Jarilla–Coffea extract eyelashes 
and eyebrow gels was demonstrated. In all healthy premeno-
pausal and postmenopausal women with scant eyelashes and 
eyebrows, both these gels were capable of increasing the 
eyelash and eyebrow growth in relation to thickness in all 
women treated, improving the hair appearance by this way. 
Moreover, other parameters such as the eyelash maximal 
length (that increased in 55.6% of the volunteers) and the eye-
brow new hairs (in 60% of the volunteers) related to growth 
were modified by this gel. However, there was no statistical 
difference with the placebo (P=0.11 and 0.749, respectively).
It could be possible that the product had increased thick-
ness of eyelash and eyebrow hair by promoting hair from telo-
gen to anagen phase. Previously, it was demonstrated that the 
plant extracts, present in the gel, were capable to induce hair 
Figure 1 effect of eyelash gel on (A) eyelash thickness and (B) length.























































Table 3 eyelash maximal length: statistical descriptors
Statistical 
descriptors
N Minimum Maximum Mean SD
active T0 9 21.5720 44.3710 34.3730 6.9594393
active TF 9 22.7930 46.4040 35.5494 7.5886040
PV TF/T0 9 –5.13 23.92 3.59% 9.04619
Placebo T0 9 22.7930 43.9620 36.0910 6.9738635
Placebo TF 9 24.8320 47.2160 35.5494 7.2176550
PV TF/T0 9 –13.67 8.95 –1.09% 8.65175
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in a randomized, prospective, open-label, single-branch, 
phase IV cohort study. The clinical study revealed that the 
lotion improves the appearance, volume and appearance of 
new hair due to an induction of hair growth, and a decrease 
of hair loss (from the moment of its application) in 84.6% 
of patients (total patients 52), after 90 days of treatment. 
The decrease in hair loss was higher in women, and the best 
results were obtained in grades I and II androgenic alopecia 
and in alopecia areata.8
The mechanism of the extracts involved in promoting 
anagen phase could be related to a modulation of PGs. It was 
demonstrated that unlike PGD2, which has an inhibitory effect, 
prostaglandin F2α and PGF2 induce hair growth. Therefore, 
PGs may be considered a pharmacological target for the treat-
Figure 2 effect of eyelash gel on (A, B) eyelash length and (C) thickness.
Notes: (A) Representative micrographs of eyelashes treated either with gel (upper) or with placebo (lower). Micrographs were taken with Fotofinder®. (B) analysis of the 
micrographs shown in (A). (C) representative micrographs of eyelashes treated with either gel (upper) or with placebo (lower). analysis of thickness was done with video 


















Table 4 eyebrow thickness: statistical descriptors
Statistical 
descriptors
N Minimum Maximum Mean SD
active T0 10 0.04 0.07 0.0550 0.00850
active T60 10 0.04 0.07 0.0600 0.009129
active PV 10 0.00% 20.00% 9.1667% 6.19886%
Placebo T0 10 0.04 0.07 0.0580 0.01033
Placebo T60 10 0.04 0.07 0.0580 0.01033
Placebo PV 10 0.00% 0.00% 0.0000% 0.00000%
Abbreviation: PV, percent variation.
from telogen to anagen phase in C3H mice.7 Moreover, the 
capacity of a lotion, made with the two extracts, in stimulating 
hair growth in humans has previously been determined. Such 
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a natural product that improves eyelash and eyebrow appearance
ment of androgenetic alopecia.9,10 In line with these findings, 
it was found that inhibitors of PGs synthesis, such as aspirin, 
indomethacin, and ibuprofen, can inhibit hair growth.11,12 The 
extracts present in the gel have flavonoids (quercetin  derivatives) 
and nordihydroguaiaretic acid (NDGA) – compounds that can 
modulate endogen PGs. For example, NDGA is an inhibitor of 
lipooxigense, therefore, this polyphenol could increase the PG 
synthesis, by activating  cyclooxigenase (COX) pathway, thus 
Figure 3 effect of eyebrow gel on (A–D) eyebrow growth  and (E, F) thickness.
Notes: (A, B) Representative micrographs of eyebrows treated either with gel (upper) or with placebo (lower). Micrographs were taken with Fotofinder®. (C, D) analysis 
of the micrographs shown in (A, B). (E, F) representative micrographs of eyebrows treated either with gel (upper) or with placebo (lower). analysis of thickness was done 



































Table 5 eyebrow new hairs: statistical descriptors
Statistical 
descriptors
N Minimum Maximum Mean SD
active T0 10 56 204 119.70 57.337
active TF 10 60 269 130.70 66.369
active PV 10 –36% 56% 12.57% 29.776%
Placebo T0 10 61 162 118.30 32.308
Placebo TF 10 53 206 123.80 49.571
Placebo PV 10 –24% 62% 3.94% 27.362%
Abbreviation: PV, percent variation.
Table 6 eyebrow total area with hair: statistical descriptors
Statistical 
descriptors
N Minimum Maximum Mean SD
active T0 10 0.15924 0.84720 0.4350210 0.23240888
active TF 10 0.17062 0.76764 0.4448500 0.20246945
active PV 10 –51.13% 132.60% 15.5322% 51.52571%
Placebo T0 10 0.14609 0.75613 0.4002340 0.16880262
Placebo TF 10 0.12053 0.75707 0.4184350 0.19337064
Placebo PV 10 –24.83% 84.87% 5.6920% 33.34614%
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increasing eyelash growth. Moreover, and depending on its 
concentration, NDGA may also inhibit the synthesis of PGD2 
through the inhibition of COX-1. In addition, it has also been 
demonstrated that the flavonoids present in Chinese herbs, 
such as amentoflavone, quercetin-3-O-rutinoside (rutin), and 
hinokiflavone, are PGD2 inhibitors with good pharmacokinetic 
properties and high efficacy in the treatment of hair loss.13
By other way, it is known that ROS can modulate the bal-
ance between the anagen and telogen phases, causing damage 
to DNA, cell proteins, and lipids leading to cell arrest and 
follicular cell death.14 These events are known to promote the 
hair follicle to shift from the anagen to the telogen phase, or 
hair loss phase. Normally, the ROS levels are controlled by 
the activity of antioxidant enzymes, such as superoxide dis-
mutase (SOD), catalase (CAT), and peroxidase (Px); however, 
there are cases in which the ROS production exceeds their 
metabolism rate leading to different diseases. It is known 
that the superoxide anion is involved in the occurrence of 
alopecia, since this free radical interferes with the production 
of nitric oxide, which is an essential factor for hair growth.15
The extracts present in the gel are also known to have 
antioxidant activities, such as Px, CAT, and SOD-like activi-
ties.16,17 Therefore, the effects observed after the treatment 
with the gel could also be related to these biological activities 
exerted by the extracts.
It is thought that herb-based formulations may influence 
hair growth by stimulating or inhibiting a variety of growth 
factors, cytokines, hormones, enzymes, as well as through 
the modulation of signaling pathways. Some herbs and their 
active constituents allow maintaining the hair growth cycle in 
the anagen phase, while others inhibit hair apoptosis during 
the catagen phase.
The fact that the product increased hair length and the 
appearance of new hairs but not in a significant manner sug-
gests that a longer treatment is necessary.
It is noteworthy that neither ocular nor dermal side effects 
were observed with Jarilla–Coffea extract gel in contrast with 
the products used nowadays to increase eyelash or eyebrow 
growth or for alopecia treatment.
Conclusion
This study concludes that the Jarilla–Coffea extract gel was 
capable of improving eyelash and eyebrow growth by inducing 
hair thickness, and also the appearance of new hairs and hair 
length were changed, without exerting local adverse effects.
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